{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:40:09Z","timestamp":1750527609986,"version":"3.41.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This narrative review analyzes the customization of menopause hormone therapy (MHT) for osteoporosis prevention and treatment in the context of the patients' age and menopausal age. In short, MHT is indicated in most women suffering from menopause before the age of 45 years except for breast cancer survivors. These women should be treated with MHT until the age of 50 years. For women who have entered menopause at around the age of 50 years, risks associated with MHT are low, and MHT is a safe option, provided there is an indication for it. We suggest that pursuing MHT entails different risks than initiating it, after the age of 60 years. In both cases, advantages and risks should be evaluated. We suggest using risk calculators to assess the magnitude of these risks and choosing regimens that entail the lowest breast and thrombosis risks.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000592","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T13:18:06Z","timestamp":1653052686000},"page":"204-207","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Menopause Hormone Therapy in the Management of Postmenopausal Osteoporosis"],"prefix":"10.1097","volume":"28","author":[{"given":"Serge","family":"Rozenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Vandromme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perrine","family":"Revercez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Valcarenghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Joris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/bmj.3.5879.515","article-title":"Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy","volume":"3","year":"1973","journal-title":"Br Med J"},{"key":"bib2-20250621","first-page":"459","article-title":"Bone mass in postmenopausal women after withdrawal of oestrogen\/gestagen replacement therapy","volume":"1","year":"1981","journal-title":"Lancet"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0378-5122(93)90048-M","article-title":"Decrease of bone mineral density during estrogen substitution therapy","volume":"17","year":"1993","journal-title":"Maturitas"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-117-1-1","article-title":"Treatment of postmenopausal osteoporosis with transdermal estrogen","volume":"117","year":"1992","journal-title":"Ann Intern Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"358","DOI":"10.7326\/0003-4819-108-3-358","article-title":"Postmenopausal estrogen use and coronary atherosclerosis","volume":"108","year":"1988","journal-title":"Ann Intern Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM199109123251102","article-title":"Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"bib7-20250621","first-page":"311","article-title":"The Women's Health Initiative: studying interventions over the long term","volume":"8","year":"1995","journal-title":"Clin Lab Sci"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMp1514242","article-title":"Menopause management\u2014getting clinical care back on track","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrendo.2013.17","article-title":"Postmenopausal hormone therapy: risks and benefits [published online February 19, 2013]","volume":"9","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/GME.0000000000001561","article-title":"A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety","volume":"27","year":"2020","journal-title":"Menopause"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects [published online December 13, 2012]","volume":"34","year":"2013","journal-title":"Endocr Rev"},{"key":"bib13-20250621","first-page":"2020-10-1","article-title":"Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference","volume":"9","year":"2020","journal-title":"Drugs Context"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0003-4819-27-6-861","article-title":"Osteoporosis","volume":"27","year":"1947","journal-title":"Ann Intern Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1210\/jcem-71-4-836","article-title":"17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women","volume":"71","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S8756-3282(99)00076-9","article-title":"A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group","volume":"24","year":"1999","journal-title":"Bone"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0022-4731(89)90092-7","article-title":"Evidence for a direct effect of estrogen on bone cells in vitro","volume":"34","year":"1989","journal-title":"J Steroid Biochem"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1152\/physrev.00033.2015","article-title":"Estrogens and androgens in skeletal physiology and pathophysiology","volume":"97","year":"2017","journal-title":"Physiol Rev"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1210\/er.2009-0024","article-title":"From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis [published online January 5, 2010]","volume":"31","year":"2010","journal-title":"Endocr Rev"},{"key":"bib20-20250621","first-page":"691","article-title":"The relationship between bone and reproductive hormones beyond estrogens and androgens [published correction appears in Endocr Rev 2021;42(6):872]","volume":"42","year":"2021","journal-title":"Endocr Rev"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(10)60355-8","article-title":"Primary ovarian insufficiency [published online August 11, 2010]","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"101577","DOI":"10.1016\/j.beem.2021.101577","article-title":"Menopausal hormone therapy and breast cancer risk","volume":"35","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12020-018-1746-6","article-title":"Association between age at menopause and fracture risk: a systematic review and meta-analysis [published online September 10, 2018]","volume":"63","year":"2019","journal-title":"Endocrine"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis","volume":"1","year":"2016","journal-title":"JAMA Cardiol"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/humrep\/dew027","article-title":"ESHRE guideline: management of women with premature ovarian insufficiency [published online March 22, 2016]","volume":"31","year":"2016","journal-title":"Hum Reprod"},{"key":"bib26-20250621","first-page":"hox007","article-title":"HRT for women with premature ovarian insufficiency: a comprehensive review","volume":"2017","year":"2017","journal-title":"Hum Reprod Open"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits [published online January 17, 2019]","volume":"153","year":"2019","journal-title":"Gynecol Oncol"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1067\/mob.2000.106595","article-title":"Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss","volume":"183","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/01.AOG.0000137833.43248.79","article-title":"Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial","volume":"104","year":"2004","journal-title":"Obstet Gynecol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0800743","article-title":"The effects of tibolone in older postmenopausal women","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/01.gme.0000184425.73567.12","article-title":"Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects [published online November 8, 2005]","volume":"12","year":"2005","journal-title":"Menopause"},{"key":"bib32-20250621","first-page":"287","article-title":"Menopausal hormone therapy use in 17 European countries during the last decade [published correction appears in Maturitas 2015;81(1):237\u2013238]","volume":"79","year":"2014","journal-title":"Maturitas"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","year":"2004","journal-title":"JAMA"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/aje\/kwaa210","article-title":"Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50\u201359 years of age","volume":"190","year":"2021","journal-title":"Am J Epidemiol"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.maturitas.2008.10.009","article-title":"The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy [published online November 22, 2008]","volume":"61","year":"2008","journal-title":"Maturitas"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/13697137.2011.570590","article-title":"Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health","volume":"14","year":"2011","journal-title":"Climacteric"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline [published online October 7, 2015]","volume":"100","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00198-020-05497-8","article-title":"Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? [published online July 8, 2020]","volume":"31","year":"2020","journal-title":"Osteoporos Int"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archinte.168.8.861","article-title":"Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy","volume":"168","year":"2008","journal-title":"Arch Intern Med"},{"key":"bib40-20250621","first-page":"k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases [published correction appears in BMJ 2019;364:1162]","volume":"364","year":"2019","journal-title":"BMJ"},{"key":"bib41-20250621","first-page":"302","article-title":"No increase in fractures after stopping hormone therapy: results from the Women's Health Initiative","volume":"102","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"bib42-20250621","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/j.1538-7836.2012.04919.x","article-title":"Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study","volume":"10","year":"2012","journal-title":"J Thromb Haemost"},{"key":"bib43-20250621","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/ATVBAHA.109.196022","article-title":"Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study [published online October 15, 2009]","volume":"30","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"bib44-20250621","first-page":"dgaa073","article-title":"Underlying breast cancer risk and menopausal hormone therapy","volume":"105","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"bib45-20250621","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/PL00004173","article-title":"Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden","volume":"11","year":"2000","journal-title":"Osteoporos Int"},{"key":"bib46-20250621","doi-asserted-by":"crossref","first-page":"e10532","DOI":"10.1002\/jbm4.10532","article-title":"Independent external validation of FRAX and Garvan Fracture Risk Calculators: a sub-study of the FRISBEE cohort","volume":"5","year":"2021","journal-title":"JBMR Plus"},{"key":"bib47-20250621","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1002\/cncr.33767","article-title":"Performance of the IBIS\/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative [published online July 6, 2021]","volume":"127","year":"2021","journal-title":"Cancer"},{"key":"bib48-20250621","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","article-title":"Probability of stroke: a risk profile from the Framingham Study","volume":"22","year":"1991","journal-title":"Stroke"},{"key":"bib49-20250621","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study [published online January 22, 2008]","volume":"117","year":"2008","journal-title":"Circulation"},{"key":"bib50-20250621","first-page":"e506","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association [published online November 30, 2020]","volume":"142","year":"2020","journal-title":"Circulation"},{"key":"bib51-20250621","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/01.AOG.0000431053.33593.2d","article-title":"ACOG Committee Opinion No. 565: hormone therapy and heart disease","volume":"121","year":"2013","journal-title":"Obstet Gynecol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:00:32Z","timestamp":1750525232000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000592","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"type":"electronic","value":"1540-336X"},{"type":"print","value":"1528-9117"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}